Cartesian Therapeutics, Inc.
RNAC · XNASCIK 1453687fmd_1ADVRYAKWGZ9E8YNMMTCX328JKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 0 | 1 | 7 | 17 | 85 | 111 | 26 | 39 | 3 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Research and development | 30 | 45 | 48 | 43 | 55 | 69 | 72 | 71 | 45 | 58 |
| Total operating expenses | 43 | 64 | 66 | 59 | 73 | 90 | 96 | 112 | 83 | 146 |
| Operating income | (35) | (64) | (65) | (52) | (57) | (5) | 15 | (86) | (44) | (143) |
| Interest expense | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 0 | – |
| Interest and investment income | – | – | – | – | – | – | – | 5 | 7 | 7 |
| Other non-operating income (expense) | 0 | (0) | 0 | (1) | 0 | 0 | 0 | 1 | (33) | 4 |
| Income before taxes | – | – | – | (55) | (69) | (10) | 35 | (239) | (77) | (139) |
| Income tax expense | – | – | – | 0 | 0 | 16 | (1) | (19) | 0 | (9) |
| Net income from continuing operations | – | – | – | (55) | (69) | (26) | 35 | (220) | (77) | (130) |
| Net income | (36) | (65) | (65) | (55) | (69) | (26) | 35 | (220) | (77) | (130) |
| Net income to common shareholders | (41) | (65) | (65) | (55) | (69) | (26) | 35 | (257) | (77) | (130) |